Comparison of Rhinitis Treatments Using MASK-air ® Data and Considering the Minimal Important Difference
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Outros Autores: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10400.17/4261 |
Resumo: | Background: Different treatments exist for allergic rhinitis (AR), including pharmacotherapy and allergen immunotherapy (AIT), but they have not been compared using direct patient data (i.e., "real-world data"). We aimed to compare AR pharmacological treatments on (i) daily symptoms, (ii) frequency of use in co-medication, (iii) visual analogue scales (VASs) on allergy symptom control considering the minimal important difference (MID) and (iv) the effect of AIT. Methods: We assessed the MASK-air® app data (May 2015-December 2020) by users self-reporting AR (16-90 years). We compared eight AR medication schemes on reported VAS of allergy symptoms, clustering data by the patient and controlling for confounding factors. We compared (i) allergy symptoms between patients with and without AIT and (ii) different drug classes used in co-medication. Results: We analysed 269,837 days from 10,860 users. Most days (52.7%) involved medication use. Median VAS levels were significantly higher in co-medication than in monotherapy (including the fixed combination azelastine-fluticasone) schemes. In adjusted models, azelastine-fluticasone was associated with lower average VAS global allergy symptoms than all other medication schemes, while the contrary was observed for oral corticosteroids. AIT was associated with a decrease in allergy symptoms in some medication schemes. A difference larger than the MID compared to no treatment was observed for oral steroids. Azelastine-fluticasone was the drug class with the lowest chance of being used in co-medication (adjusted OR = 0.75; 95% CI = 0.71-0.80). Conclusion: Median VAS levels were higher in co-medication than in monotherapy. Patients with more severe symptoms report a higher treatment, which is currently not reflected in guidelines. |
id |
RCAP_6fd1bd77a083ebf1c6c0ee90339be987 |
---|---|
oai_identifier_str |
oai:repositorio.chlc.min-saude.pt:10400.17/4261 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Comparison of Rhinitis Treatments Using MASK-air ® Data and Considering the Minimal Important DifferenceAllergen immunotherapy;Allergic rhinitisCo-medicationMultivariable mixed-effects modelReal-world dataHDE ALERBackground: Different treatments exist for allergic rhinitis (AR), including pharmacotherapy and allergen immunotherapy (AIT), but they have not been compared using direct patient data (i.e., "real-world data"). We aimed to compare AR pharmacological treatments on (i) daily symptoms, (ii) frequency of use in co-medication, (iii) visual analogue scales (VASs) on allergy symptom control considering the minimal important difference (MID) and (iv) the effect of AIT. Methods: We assessed the MASK-air® app data (May 2015-December 2020) by users self-reporting AR (16-90 years). We compared eight AR medication schemes on reported VAS of allergy symptoms, clustering data by the patient and controlling for confounding factors. We compared (i) allergy symptoms between patients with and without AIT and (ii) different drug classes used in co-medication. Results: We analysed 269,837 days from 10,860 users. Most days (52.7%) involved medication use. Median VAS levels were significantly higher in co-medication than in monotherapy (including the fixed combination azelastine-fluticasone) schemes. In adjusted models, azelastine-fluticasone was associated with lower average VAS global allergy symptoms than all other medication schemes, while the contrary was observed for oral corticosteroids. AIT was associated with a decrease in allergy symptoms in some medication schemes. A difference larger than the MID compared to no treatment was observed for oral steroids. Azelastine-fluticasone was the drug class with the lowest chance of being used in co-medication (adjusted OR = 0.75; 95% CI = 0.71-0.80). Conclusion: Median VAS levels were higher in co-medication than in monotherapy. Patients with more severe symptoms report a higher treatment, which is currently not reflected in guidelines.WileyRepositório do Centro Hospitalar Universitário de Lisboa Central, EPESousa‐Pinto, BSchünemann, HJSá‐Sousa, AVieira, RJAmaral, RAnto, JMKlimek, LCzarlewski, WMullol, JPfaar, OBedbrook, ABrussino, LKvedariene, VLarenas‐Linnemann, DOkamoto, YVentura, MTAgache, IAnsotegui, IJBergmann, KCBosnic‐Anticevich, SBrozek, JCanonica, GWCardona, VCarreiro‐Martins, PCasale, TCecchi, LChivato, TChu, DKCingi, CCosta, EMCruz, AADel Giacco, SDevillier, PEklund, PFokkens, WJGemicioglu, BHaahtela, TIvancevich, JCIspayeva, ZJutel, MKuna, PKaidashev, IKhaitov, MKraxner, HLaune, DLipworth, BLouis, RMakris, MMonti, RMorais‐Almeida, MMösges, RNiedoszytko, MPapadopoulos, NGPatella, VPham‐Thi, NRegateiro, FSReitsma, SRouadi, PWSamolinski, BSheikh, ASova, MTodo‐Bom, ATaborda‐Barata, LToppila‐Salmi, SSastre, JTsiligianni, IValiulis, AVandenplas, OWallace, DWaserman, SYorgancioglu, AZidarn, MZuberbier, TFonseca, JA.Bousquet, J2022-11-03T16:15:45Z20222022-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.17/4261engAllergy. 2022 Oct;77(10):3002-301410.1111/all.15371info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-03-10T09:46:05Zoai:repositorio.chlc.min-saude.pt:10400.17/4261Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T17:21:35.270400Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Comparison of Rhinitis Treatments Using MASK-air ® Data and Considering the Minimal Important Difference |
title |
Comparison of Rhinitis Treatments Using MASK-air ® Data and Considering the Minimal Important Difference |
spellingShingle |
Comparison of Rhinitis Treatments Using MASK-air ® Data and Considering the Minimal Important Difference Sousa‐Pinto, B Allergen immunotherapy; Allergic rhinitis Co-medication Multivariable mixed-effects model Real-world data HDE ALER |
title_short |
Comparison of Rhinitis Treatments Using MASK-air ® Data and Considering the Minimal Important Difference |
title_full |
Comparison of Rhinitis Treatments Using MASK-air ® Data and Considering the Minimal Important Difference |
title_fullStr |
Comparison of Rhinitis Treatments Using MASK-air ® Data and Considering the Minimal Important Difference |
title_full_unstemmed |
Comparison of Rhinitis Treatments Using MASK-air ® Data and Considering the Minimal Important Difference |
title_sort |
Comparison of Rhinitis Treatments Using MASK-air ® Data and Considering the Minimal Important Difference |
author |
Sousa‐Pinto, B |
author_facet |
Sousa‐Pinto, B Schünemann, HJ Sá‐Sousa, A Vieira, RJ Amaral, R Anto, JM Klimek, L Czarlewski, W Mullol, J Pfaar, O Bedbrook, A Brussino, L Kvedariene, V Larenas‐Linnemann, D Okamoto, Y Ventura, MT Agache, I Ansotegui, IJ Bergmann, KC Bosnic‐Anticevich, S Brozek, J Canonica, GW Cardona, V Carreiro‐Martins, P Casale, T Cecchi, L Chivato, T Chu, DK Cingi, C Costa, EM Cruz, AA Del Giacco, S Devillier, P Eklund, P Fokkens, WJ Gemicioglu, B Haahtela, T Ivancevich, JC Ispayeva, Z Jutel, M Kuna, P Kaidashev, I Khaitov, M Kraxner, H Laune, D Lipworth, B Louis, R Makris, M Monti, R Morais‐Almeida, M Mösges, R Niedoszytko, M Papadopoulos, NG Patella, V Pham‐Thi, N Regateiro, FS Reitsma, S Rouadi, PW Samolinski, B Sheikh, A Sova, M Todo‐Bom, A Taborda‐Barata, L Toppila‐Salmi, S Sastre, J Tsiligianni, I Valiulis, A Vandenplas, O Wallace, D Waserman, S Yorgancioglu, A Zidarn, M Zuberbier, T Fonseca, JA. Bousquet, J |
author_role |
author |
author2 |
Schünemann, HJ Sá‐Sousa, A Vieira, RJ Amaral, R Anto, JM Klimek, L Czarlewski, W Mullol, J Pfaar, O Bedbrook, A Brussino, L Kvedariene, V Larenas‐Linnemann, D Okamoto, Y Ventura, MT Agache, I Ansotegui, IJ Bergmann, KC Bosnic‐Anticevich, S Brozek, J Canonica, GW Cardona, V Carreiro‐Martins, P Casale, T Cecchi, L Chivato, T Chu, DK Cingi, C Costa, EM Cruz, AA Del Giacco, S Devillier, P Eklund, P Fokkens, WJ Gemicioglu, B Haahtela, T Ivancevich, JC Ispayeva, Z Jutel, M Kuna, P Kaidashev, I Khaitov, M Kraxner, H Laune, D Lipworth, B Louis, R Makris, M Monti, R Morais‐Almeida, M Mösges, R Niedoszytko, M Papadopoulos, NG Patella, V Pham‐Thi, N Regateiro, FS Reitsma, S Rouadi, PW Samolinski, B Sheikh, A Sova, M Todo‐Bom, A Taborda‐Barata, L Toppila‐Salmi, S Sastre, J Tsiligianni, I Valiulis, A Vandenplas, O Wallace, D Waserman, S Yorgancioglu, A Zidarn, M Zuberbier, T Fonseca, JA. Bousquet, J |
author2_role |
author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author |
dc.contributor.none.fl_str_mv |
Repositório do Centro Hospitalar Universitário de Lisboa Central, EPE |
dc.contributor.author.fl_str_mv |
Sousa‐Pinto, B Schünemann, HJ Sá‐Sousa, A Vieira, RJ Amaral, R Anto, JM Klimek, L Czarlewski, W Mullol, J Pfaar, O Bedbrook, A Brussino, L Kvedariene, V Larenas‐Linnemann, D Okamoto, Y Ventura, MT Agache, I Ansotegui, IJ Bergmann, KC Bosnic‐Anticevich, S Brozek, J Canonica, GW Cardona, V Carreiro‐Martins, P Casale, T Cecchi, L Chivato, T Chu, DK Cingi, C Costa, EM Cruz, AA Del Giacco, S Devillier, P Eklund, P Fokkens, WJ Gemicioglu, B Haahtela, T Ivancevich, JC Ispayeva, Z Jutel, M Kuna, P Kaidashev, I Khaitov, M Kraxner, H Laune, D Lipworth, B Louis, R Makris, M Monti, R Morais‐Almeida, M Mösges, R Niedoszytko, M Papadopoulos, NG Patella, V Pham‐Thi, N Regateiro, FS Reitsma, S Rouadi, PW Samolinski, B Sheikh, A Sova, M Todo‐Bom, A Taborda‐Barata, L Toppila‐Salmi, S Sastre, J Tsiligianni, I Valiulis, A Vandenplas, O Wallace, D Waserman, S Yorgancioglu, A Zidarn, M Zuberbier, T Fonseca, JA. Bousquet, J |
dc.subject.por.fl_str_mv |
Allergen immunotherapy; Allergic rhinitis Co-medication Multivariable mixed-effects model Real-world data HDE ALER |
topic |
Allergen immunotherapy; Allergic rhinitis Co-medication Multivariable mixed-effects model Real-world data HDE ALER |
description |
Background: Different treatments exist for allergic rhinitis (AR), including pharmacotherapy and allergen immunotherapy (AIT), but they have not been compared using direct patient data (i.e., "real-world data"). We aimed to compare AR pharmacological treatments on (i) daily symptoms, (ii) frequency of use in co-medication, (iii) visual analogue scales (VASs) on allergy symptom control considering the minimal important difference (MID) and (iv) the effect of AIT. Methods: We assessed the MASK-air® app data (May 2015-December 2020) by users self-reporting AR (16-90 years). We compared eight AR medication schemes on reported VAS of allergy symptoms, clustering data by the patient and controlling for confounding factors. We compared (i) allergy symptoms between patients with and without AIT and (ii) different drug classes used in co-medication. Results: We analysed 269,837 days from 10,860 users. Most days (52.7%) involved medication use. Median VAS levels were significantly higher in co-medication than in monotherapy (including the fixed combination azelastine-fluticasone) schemes. In adjusted models, azelastine-fluticasone was associated with lower average VAS global allergy symptoms than all other medication schemes, while the contrary was observed for oral corticosteroids. AIT was associated with a decrease in allergy symptoms in some medication schemes. A difference larger than the MID compared to no treatment was observed for oral steroids. Azelastine-fluticasone was the drug class with the lowest chance of being used in co-medication (adjusted OR = 0.75; 95% CI = 0.71-0.80). Conclusion: Median VAS levels were higher in co-medication than in monotherapy. Patients with more severe symptoms report a higher treatment, which is currently not reflected in guidelines. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-11-03T16:15:45Z 2022 2022-01-01T00:00:00Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10400.17/4261 |
url |
http://hdl.handle.net/10400.17/4261 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Allergy. 2022 Oct;77(10):3002-3014 10.1111/all.15371 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Wiley |
publisher.none.fl_str_mv |
Wiley |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799131310924496896 |